Atossa Therapeutics (NASDAQ:ATOS) Stock Passes Above 200 Day Moving Average – Here’s What Happened

Atossa Therapeutics, Inc. (NASDAQ:ATOS) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.39 and traded as high as $1.50. Atossa Therapeutics shares last traded at $1.50, with a volume of 362,114 shares trading hands.

Wall Street Analysts Forecast Growth

ATOS has been the subject of a number of analyst reports. Ascendiant Capital Markets upped their target price on Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a report on Wednesday, September 11th. StockNews.com lowered Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 12th. Finally, HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Atossa Therapeutics in a research note on Monday, August 12th.

Atossa Therapeutics Trading Down 3.4 %

The firm has a market capitalization of $177.32 million, a price-to-earnings ratio of -5.88 and a beta of 1.20. The company has a fifty day moving average price of $1.42 and a two-hundred day moving average price of $1.39.

Atossa Therapeutics (NASDAQ:ATOS) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. As a group, equities research analysts expect that Atossa Therapeutics, Inc. will post -0.22 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp lifted its holdings in Atossa Therapeutics by 3,160.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after buying an additional 399,041 shares during the last quarter. Cetera Advisors LLC bought a new stake in shares of Atossa Therapeutics during the 1st quarter worth $72,000. Virtu Financial LLC acquired a new stake in shares of Atossa Therapeutics in the first quarter worth $151,000. Rhumbline Advisers purchased a new stake in shares of Atossa Therapeutics during the second quarter worth $161,000. Finally, Vanguard Group Inc. raised its holdings in shares of Atossa Therapeutics by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after acquiring an additional 78,269 shares in the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.